@proceedings{Keir_H-2022_99296,
title = {A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial},
author = {Keir, H. and Long, M. and Abo leyah, H. and Giam, Y. and Vadiveloo, T. and Pembridge, T. and Hull, R. and Delgado, L. and Band, M. and McLaren-Neil, F. and Adamson, S. and Lahnsteiner, E. and Gilmour, A. and Hughes, C. and New, B. and Connell, D. and Dowey, R. and Turton, H. and Richardson, H. and Cassidy, D. and Cooper, J. and Suntharalingam, J. and Diwakar, L. and Russell, P. and Underwood, J. and Hicks, A. and Dosanjh, D. and Sage, E. and Dhasmana, D. and Spears, M. and Thompson, R. and Brightling, C. and Patel, M. and George, J. and Condliffe, A. and Shoemark, A. and Maclennan, G. and Chalmers, J.},
month = {may},
year = {2022},
abstract = {Rationale: Markers of neutrophilic inflammation, including neutrophil serine proteases, are increased in severe and fatal COVID-19 infection. We investigated whether treatment with Brensocatib, an oral inhibitor of Dipeptidyl Peptidase-1 (DPP1) which reduces neutrophilic inflammation, would improve clinical outcomes in hospitalized patients with COVID-19. Methods: A randomized, double-blind, placebo-controlled trial was conducted in 14 UK hospitals(ISRCTN30564012). Patients were randomized to receive Brensocatib (25mg/day) or placebo for28 days. Inclusion criteria required confirmed SARS-CoV-2 infection with at least one risk factor for severe disease (requirement for supplementary oxygen, oxygen saturation less than 94% on room air, radiographic infiltrates, evidence of pulmonary involvement in physical examination or lymphocyte count},
journal = {American Thoracic Society International Conference 2022},
publisher = {ATS journals},
url = {https://doi.org/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A5055},
}
